Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encore Medical/BioHorizons merger pulled

This article was originally published in The Gray Sheet

Executive Summary

Dental implant maker BioHorizons will pursue growth as an independent company after mutually agreeing to terminate a $36 mil., May 17 merger agreement with Encore, the firm says (1"The Gray Sheet" May 24, 2004, p. 25). Under the deal, either party could back out if it failed to close by Sept. 1. SEC's unexpected decision to review a merger-related filing caused a delay, Encore explains. The filing, which did not result in SEC concerns, was required since BioHorizons has over 90 shareholders, BioHorizons notes. BioHorizons may have soured on the cash and stock deal in light of Encore's 40% decrease in stock price from May 18-Sept. 1 amid weakness in the broader stock market. The firm also may have felt Encore would be preoccupied with its $360 mil. purchase of Empi, announced Aug. 9 (2"The Gray Sheet" Aug. 16, 2004, p. 18). Encore expects the Empi deal to close in October...

Related Content

UsernamePublicRestriction

Register

MT020869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel